Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | UBE2M | P61081 | 6/20 | 0.35 |
| ▸ | DCUN1D1 | Q96GG9 | 6/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | GFER | P55789 | 1/20 | 0.33 |
| ▸ | HDAC4 | P56524 | 4/20 | 0.33 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.31 |
| ▸ | TSHR | P16473 | 2/20 | 0.31 |
| ▸ | HTT | P42858 | 2/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | ILK | Q13418 | 1/20 | 0.31 |
| ▸ | TP53 | P04637 | 1/20 | 0.30 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.30 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24251984 | 0.94 | NPC1 (0.36) | NPC1RAB9AMEN1KMT2AUBE2M | |
| SCHEMBL20570881 | 0.79 | CYP11B1 (0.39) | NPC1RAB9AMEN1KMT2AUBE2M | |
| SCHEMBL24251903 | 0.77 | NPC1 (0.40) | NPC1RAB9AMEN1KMT2AUBE2M | |
| SCHEMBL30082324 | 0.77 | NPC1 (0.40) | NPC1RAB9AMEN1KMT2AUBE2M | |
| SCHEMBL24251980 | 0.75 | SMN1; SMN2 (0.53) | NPC1RAB9AKMT2AALDH1A1GAA | |
| SCHEMBL30580446 | 0.73 | P2RX7 (0.31) | — | |
| SCHEMBL24251981 | 0.73 | NPC1 (0.49) | NPC1RAB9AMEN1KMT2AUBE2M | |
| SCHEMBL26086246 | 0.73 | P2RX7 (0.31) | — | |
| SCHEMBL30082439 | 0.72 | ALDH1A1 (0.36) | NPC1RAB9AMEN1KMT2AUBE2M | |
| SCHEMBL24251927 | 0.72 | ALDH1A1 (0.36) | NPC1RAB9AMEN1KMT2AUBE2M |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116096720-B | Dihydropyrrolo [2,3-d ] pyridazin-7-one derivatives, preparation method and application thereof | 上海和誉生物医药科技有限公司 | 2025-02-07 | — | — | CN | disclosed |
| CN-115867547-B | 1H-pyrazole-4-amide derivative, preparation method and application thereof | 上海和誉生物医药科技有限公司 | 2024-12-20 | — | — | CN | disclosed |
| CN-115485281-B | FGFR and mutation inhibitor thereof, and preparation method and application thereof | 上海和誉生物医药科技有限公司 | 2023-11-21 | — | — | CN | disclosed |
| US-20230303575-A1 | FGFR AND MUTATION INHIBITOR THEREOF, PREPARATION METHOD THEREFOR AND USE THEREOF | ABBISKO THERAPEUTICS CO., LTD. (CN) | 2023-09-28 | — | — | US | disclosed |
| US-20230303575-A1 | FGFR AND MUTATION INHIBITOR THEREOF, PREPARATION METHOD THEREFOR AND USE THEREOF | ABBISKO THERAPEUTICS CO., LTD. (CN) | 2023-09-28 | — | — | US | disclosed |
| CN-116096720-A | Dihydropyrrolo [2,3-d ] pyridazin-7-one derivatives, preparation method and application thereof | 上海和誉生物医药科技有限公司 | 2023-05-09 | — | — | CN | disclosed |
| EP-4169922-A1 | FGFR AND MUTATION INHIBITOR THEREOF, AND PREPARATION METHOD THEREFOR AND USE THEREOF | Abbisko Therapeutics Co., Ltd. (CN) | 2023-04-26 | — | — | EP | disclosed |
| CN-115867547-A | 1H-pyrazole-4-amide derivative, and preparation method and application thereof | 上海和誉生物医药科技有限公司 | 2023-03-28 | — | — | CN | disclosed |
| CN-115485281-A | FGFR and mutation inhibitor thereof, and preparation method and application thereof | 上海和誉生物医药科技有限公司 | 2022-12-16 | — | — | CN | disclosed |
| WO-2022042613-A1 | 1H-PYRAZOL-4-AMIDE DERIVATIVE, PREPARATION METHOD THEREFOR, AND USE THEREOF | 上海和誉生物医药科技有限公司 | 2022-03-03 | — | — | WO | disclosed |
| WO-2022042612-A1 | DIHYDROPYRROLO[2,3-D]PYRIDAZIN-7-ONE DERIVATIVE, PREPARATION METHOD THEREFOR, AND APPLICATION THEREOF | 上海和誉生物医药科技有限公司 | 2022-03-03 | — | — | WO | disclosed |
| WO-2022033532-A1 | FGFR AND MUTATION INHIBITOR THEREOF, AND PREPARATION METHOD THEREFOR AND USE THEREOF | 上海和誉生物医药科技有限公司 | 2022-02-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230303575-A1 | FGFR AND MUTATION INHIBITOR THEREOF, PREPARATION METHOD THEREFOR AND USE THEREOF | FGFR3, FGFR1, FGFR4 | NPC1 2173/4885RAB9A 3048/4885MEN1 1023/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.